Recent advances in chronic lymphocytic leukemia.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 137-143
Article
Dans Anglais
| IMSEAR
| ID: sea-144564
ABSTRACT
Chronic lymphocytic leukemia (CLL) was largely considered to be a disease of slow progression, standard treatment with Chlorambucil and having almost similar prognosis. With the introduction of molecular methods for understanding the disease pathophysiology in CLL there has been a remarkable change in the approach towards the disease. The variation in B-cell receptor response and immunoglobulin heavy chain variable region (IGHV) mutation, genetic aberration and defect in apoptosis and proliferation has had an impact on therapy initiation and prognosis. Early diagnosis of molecular variant is therefore necessary in CLL.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pronostic
/
Humains
/
Région variable d'immunoglobuline
/
Récepteurs pour l'antigène des lymphocytes B
/
Leucémie chronique lymphocytaire à cellules B
/
Protéine p53 suppresseur de tumeur
/
Aberrations des chromosomes
/
Chaines lourdes des immunoglobulines
/
ZAP-70 Protein-tyrosine kinase
/
Hyperlymphocytose
Type d'étude:
Étude pronostique
/
Étude de dépistage
langue:
Anglais
Texte intégral:
Indian J Cancer
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS